OncoMatch/Clinical Trials/NCT05899608
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Is NCT05899608 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Ivonescimab and Pembrolizumab for non-small cell lung cancer.
Treatment: Ivonescimab · Pembrolizumab — This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR actionable genomic alteration
Known actionable genomic alterations (EGFR, ALK, ROS1, and BRAF V600E) or genes for which first-line approved therapies are available.
Required: ALK actionable genomic alteration
Known actionable genomic alterations (EGFR, ALK, ROS1, and BRAF V600E) or genes for which first-line approved therapies are available.
Required: ROS1 actionable genomic alteration
Known actionable genomic alterations (EGFR, ALK, ROS1, and BRAF V600E) or genes for which first-line approved therapies are available.
Required: BRAF V600E
Known actionable genomic alterations (EGFR, ALK, ROS1, and BRAF V600E) or genes for which first-line approved therapies are available.
Required: PD-L1 (CD274) expression (testing required; no eligibility threshold specified)
Recorded measurement of the Tumor Proportion Score (TPS) or Tumor Cells (TC) for PD-L1 expression, irrespective of the PD-L1 expression, prior to randomization
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any prior therapy for NSCLC in the metastatic setting
Has received any prior therapy for NSCLC in the metastatic setting
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner University Medical Center · Phoenix, Arizona
- TMC Healthcare · Tucson, Arizona
- University of Arkansas · Little Rock, Arkansas
- LA Cancer Network · Anaheim, California
- The Oncology Institute of Hope & Innovation · Cerritos, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify